Vai al contenuto principale della pagina
| Autore: |
Meehan James
|
| Titolo: |
Cancer Biomarker Research and Personalized Medicine
|
| Pubblicazione: | Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 |
| Descrizione fisica: | 1 online resource (428 p.) |
| Soggetto topico: | Medicine and Nursing |
| Oncology | |
| Soggetto non controllato: | 1H-NMR |
| Akt/mTOR | |
| AmpliSeq | |
| anastomotic leak | |
| autophagy | |
| bioinformatics | |
| biomarker | |
| biomarkers | |
| bladder tumor | |
| breast cancer | |
| cancer biomarkers | |
| cancer vaccine | |
| chemoradiotherapy | |
| chemoresistance | |
| chemotherapy | |
| circulating tumor cells | |
| clear cell renal cell carcinoma | |
| colorectal cancer | |
| comparative oncology | |
| CREB1 | |
| cytokine signalling | |
| DNA methylation | |
| drug perturbation | |
| epigenetics | |
| exosomes | |
| FOXO3 | |
| gastric cancer | |
| GBP5 | |
| glycopeptide | |
| gp130 | |
| haptoglobin | |
| head and neck cancer | |
| head and neck squamous cell carcinoma | |
| hepatocellular carcinoma | |
| HNSCC | |
| hormone-dependent carcinogenesis | |
| HPV genotyping | |
| IL13Rα2 | |
| IL6ST | |
| immune response | |
| intestinal anastomosis | |
| JAK2 | |
| LC-MS/MS | |
| lincRNA-p21 | |
| lipidomics | |
| lipoprotein lipase | |
| lipoprotein subfractions | |
| liquid biopsy | |
| liquid-based biomarkers | |
| localized prostate cancer | |
| long non-coding RNA | |
| lymph node metastasis | |
| lymphocyte-to-monocyte ratio | |
| mass spectrometry | |
| meta-analysis | |
| microRNA | |
| middle-up-down | |
| multiphasic multidetector computed tomography | |
| n/a | |
| One Health | |
| ovarian cancer | |
| p16 expression | |
| p53 | |
| peripheral blood parameters | |
| personalized medicine | |
| precision medicine | |
| predictive biomarker | |
| predictive tools | |
| prognostic factors | |
| prognostic tools | |
| prostate cancer | |
| radiomics | |
| radioresistance | |
| radiosensitivity biomarkers | |
| radiotherapy | |
| rectal cancer | |
| renal cell carcinoma | |
| saliva | |
| secretome | |
| taxane | |
| telmisartan | |
| tissue-based biomarkers | |
| translational research | |
| transurethral resection | |
| triple-negative breast cancer | |
| tumor recurrence | |
| WHO/ISUP nuclear grade | |
| Persona (resp. second.): | MeehanJames |
| Sommario/riassunto: | Biomarkers are measures of a biological state. The treatment of individual patients based on particular factors, such as biomarkers, distinguishes standard, generalized treatment plans from personalized medicine. Even though personalized medicine is applicable to most branches of medicine, the field of oncology is perhaps where it is most easily employed. Cancer is a heterogeneous disease; although patients may be diagnosed histologically with the same cancer type, their tumors can comprise varying tumor microenvironments and molecular characteristics that can impact treatment response and prognosis. There has been a major drive over the past decade to try and realize personalized cancer medicine through the discovery and use of disease-specific biomarkers. This book, entitled "Cancer Biomarker Research and Personalized Medicine", encompasses 22 publications from colleagues working on a diverse range of cancers, including prostate, breast, ovarian, head and neck, liver, gastric, bladder, colorectal, and kidney. The biomarkers assessed in these studies include genes, intracellular or secreted proteins, exosomes, DNA, RNA, miRNA, circulating tumor cells, circulating immune cells, in addition to radiomic features. |
| Titolo autorizzato: | Cancer Biomarker Research and Personalized Medicine ![]() |
| Formato: | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione: | Inglese |
| Record Nr.: | 9910674370003321 |
| Lo trovi qui: | Univ. Federico II |
| Opac: | Controlla la disponibilità qui |